Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical ... Enrollment in the first cohort (100 mg, twice per day) has ...
We do not expect the 100-plus new branches we launched in 2024 to have a significant impact on revenues this year or next, but over the long term we expect the agents we are onboarding in 2024 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback